KalVista Pharmaceuticals (KALV) Shares Outstanding (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 11 years of Shares Outstanding (Entity) data on file, last reported at $50.3 million in Q3 2025.

• For the quarter ending Q3 2025, Shares Outstanding (Entity) rose 16.85% year-over-year to $50.3 million; the trailing twelve-month figure through Jul 2025 stood at $50.3 million (up 16.85% YoY), and the FY2025 full-year result was $49.8 million, up 17.03% from the prior year.
• Shares Outstanding (Entity) climbed to $50.3 million in Q3 2025, from $49.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $50.3 million in Q3 2025 to a low of $18.0 million in Q1 2021.
• A 5-year average of $32.7 million and a median of $28.3 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) increased 0.55% in 2022 and jumped 52.46% in 2024, its largest moves.
• Tracing KALV's Shares Outstanding (Entity) over 5 years: stood at $24.4 million in 2021, then gained by 0.65% to $24.6 million in 2022, then soared by 39.91% to $34.4 million in 2023, then soared by 43.61% to $49.4 million in 2024, then climbed by 1.83% to $50.3 million in 2025.
• Business Quant data shows KALV's Shares Outstanding (Entity) at $50.3 million in Q3 2025, $49.8 million in Q2 2025, and $49.4 million in Q4 2024.